FDA AdComm Will Review Vertex’s Off-Target Effects Data for Sickle Cell Gene Therapy
Whether Vertex Pharmaceuticals’ off-target safety analysis of its investigational sickle cell gene therapy exagamglogene autotemcel (exa-cel) is sufficient or not is the issue before an FDA advisory committee on Tuesday…